Author:

Keywords:

Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Clinical Trials, Phase III, Female, Humans, Neoplasm Recurrence, Local, Neoplasm Staging, Ovarian Neoplasms, Randomized Controlled Trials, Risk, Survival Analysis, Time Factors, Science & Technology, Life Sciences & Biomedicine, Oncology, Obstetrics & Gynecology, STAGE-I, DNA-PLOIDY, PROGNOSTIC-SIGNIFICANCE, ADJUVANT CHEMOTHERAPY, COMPARING CISPLATIN, CARCINOMA, DIFFERENTIATION, THERAPY, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, 1112 Oncology and Carcinogenesis, 1114 Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis, 3215 Reproductive medicine